Treatment Options For Intermediate/Poor-Risk Rcc

Treatment Options for Intermediate/Poor-Risk RCC

In RCC, What Is the Optimal Treatment for Intermediate/Poor-Risk Disease?

GU Oncology Now

Tian Zhang, MD, discusses intermediate/poor and favorable risk RCC patients

Immunotherapy-based combinations for advanced/metastatic renal cell carcinoma: ASCO GU 2023

Touch Medical Media Services

Second-Line Options for Poor-Risk Advanced RCC

Targeted Oncology

Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCC

PeerView Oncology

Renal cell carcinoma

UROwebinar: Management of Metastatic kidney cancer

European School of Urology

Selecting Therapy for Poor-Risk Advanced RCC

Targeted Oncology

Poor-Risk Advanced RCC: TKI Therapy & Outlook

Targeted Oncology

Selecting and Sequencing Targeted and Immunotherapy Regimens for Patients With RCC

PeerView Oncology

Immunotherapy in Renal Cell Carcinoma

UBC Urology Rounds

Treating Intermediate and Favorable-Risk Renal Cell Carcinoma

Guidelines Based Management of Localized and Locally Advanced RCC

Grand Rounds in Urology

First-line treatment options for metastatic RCC

OncBrothers: Practice-Changing Cancer Discussions

Michael Atkins, MD, considers intermediate/poor & favorable risk RCC patients

Clinically Meaningful Outcomes Among Expanding Treatment Options in RCC

PeerView Oncology

Renal Cell Carcinoma: Everything You Need To Know

Medical Centric

The challenges in treating renal cell carcinoma

Renal Cell Carcinoma: Past, Present, and Future

UNC Lineberger Cancer Network